Biotech strategic comms: What should we learn from Pharma?

A peer-to-peer discussion on which big-pharma approaches emerging biotechs should adopt, adapt, or leave behind, how med comms and Medical Affairs can scale from development to launch, and what established pharma can learn in return.

As biotech companies move from discovery toward commercialization, Medical Affairs and med comms are becoming earlier, more strategic, and more integrated.

Moderated by Dean McAlister, the webinar will explore which big-pharma disciplines translate well to emerging biotech, which need adapting, and which may be better left behind.

The discussion will explore:

• When to establish or scale Medical Affairs and med comms capabilities
• How to balance in-house and external expertise
• How evidence, publications, and stakeholder engagement can support launch readiness and demonstrate impact
• How AI, data, and evolving stakeholder expectations may shape the future
• What established pharma can learn from biotech’s pace, agility, and focus

Presentation

The 60-minute webinar will include:

• 5 minutes for introductions and opening polling
• 35 minutes for moderated discussion
• 20 minutes for audience Q&A and closing reflections

Faculty

• Dean McAlister, Moderator – Executive Vice President, Biotech Enterprise Solutions​
• Donna Holder – Formerly Daiichi Sankyo, Merck & Co, AstraZeneca​
• Wendy Fraser – Formerly Merck & Co​

REGISTER HERE

Friday 13 November | 10.00 EST / 15.00 GMT / 16.00 CET